News Related to Psilocybin

Related coverage linked through entity extraction aliases.

Compass Pathways Achieves Second Positive Phase 3 Trial for Psilocybin Depression Treatment

Feb 16, 2026

Compass Pathways announced successful results from its second Phase 3 trial of COMP360 psilocybin for treatment-resistant depression, with highly statistically significant outcomes and plans for FDA submission in Q4 2026.

Single Dose of DMT Shows Rapid Antidepressant Effects in Phase II Trial

Feb 16, 2026

A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.